secwatch.observer — SEC 8-K summary
======================================

Issuer:     IOVANCE BIOTHERAPEUTICS, INC. (IOVA)
CIK:        0001425205
Form:       8-K
Filed at:   2024-06-28T23:59:59+00:00
Accession:  0001104659-24-075997
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Iovance submits MAA to EMA for lifileucel in advanced melanoma; first of multiple global filings
--------------------------------------------------------------------------------

- MAA seeks approval for lifileucel after prior PD-1 and BRAF/MEK therapy; would be first approved TIL therapy in EU.
- Submission supported by Phase 2 C-144-01 trial data; validation expected Q3 2024; CHMP opinion in 2025.
- Additional marketing submissions planned in Canada and UK in H2 2024, and Australia in 2025.
- Targets >20,000 patients annually in U.S., EU, UK, Canada, and Australia with advanced melanoma.
- EU expansion follows U.S. accelerated approval of lifileucel (Amtagvi) in February 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1425205/000110465924075997/0001104659-24-075997-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1425205/000110465924075997/tm2418485d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-075997

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer